Table 1.
Clinicopathological and molecular features of endometrioid and non-endometrioid endometrial cancer.
| Endometrioid |
Non-endometroid |
|
|---|---|---|
| Frequency | 75–80% | 20–25% |
|
| ||
| Clinical characteristics | ||
| Median age at diagnosis | 50–60 years | 70–80 years |
| Obesity | Present | Absent |
| Hyperlipidemia | Present | Absent |
| Diabetes | Present | Absent |
| Hypertension | Present | Absent |
| Reproductive history | Frequent infertility | Normal |
| Pathological characteristics | ||
| Histology | Endometrioid | Serous, clear cells |
| Surrounding endometrium | Hyperplasia | Atrophy |
| FIGO grade | G1 and G2 | G3 |
| Myometrial invasion | Superficial | Deep |
| Nodal involvement | Infrequent | Frequent |
| Peritoneal involvement | Rare | Frequent |
| Receptor for estrogens/progesterone | + | − |
| Molecular characteristics | ||
| ARID1A | 25–50% | <10% |
| PTEN | 50–80% | <10% |
| KRAS | 20–40% | <10% |
| PIK3CA | 40–50% | 20–40% |
| PPP2R1A | <10% | 10–40% |
| CTNNB1 | 25% | 1% |
| TP53 | 10% | 80–90% |
| HER2 | 1% | 30–40% |
Abbreviations: yrs., years; FIGO, International Federation of Obstetrics and Gynecology.